SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 9.99% Stake in Taysha Gene Therapies

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 9.99% in Taysha Gene Therapies, Inc., totaling 20,673,307 shares of common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Taysha Gene Therapies, Inc.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 20,673,307 shares of Taysha Gene Therapies, Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• The calculation of beneficial ownership includes 1,885,441 shares purchasable upon the exercise of warrants held by the Reporting Persons.
• The percentage is based on 205,054,570 shares outstanding as of April 3, 2025, as reported in the company's Definitive Proxy Statement on Schedule 14A filed on April 21, 2025.
• The warrants held by the Reporting Persons have a restriction preventing their exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• Both RTW Investments and Dr. Wong share voting and dispositive power over all 20,673,307 shares.
• RTW Master Fund Ltd., an RTW Fund, has the right to receive dividends or proceeds from the sale of more than 5% of the shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership, which is inherently neutral in sentiment. It provides factual information without expressing positive or negative outlooks on the company's performance or future prospects.

Positives

• A significant institutional investor, RTW Investments, LP, and its Managing Partner, Roderick Wong, M.D., maintain a substantial 9.99% beneficial ownership stake in Taysha Gene Therapies, Inc., which could be interpreted as a signal of continued confidence in the company.

Risks

• The Reporting Persons are restricted from exercising warrants to purchase additional shares if such exercise would result in their beneficial ownership exceeding 9.99% of the outstanding shares, which limits their ability to increase their stake beyond this threshold through warrant exercise.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11."

Industry Context

This document is a regulatory disclosure of beneficial ownership by an institutional investor in a specific company and does not provide broader industry trend analysis or context.

Related Party Transactions

• RTW Investments, LP is the investment adviser to certain funds, including RTW Master Fund Ltd., which directly holds the shares of Taysha Gene Therapies, Inc.
• Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW Investments, LP, and is therefore associated with the beneficial ownership.
• RTW Master Fund Ltd., an RTW Fund, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the Shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence investor perception and potentially stock liquidity.
• Company Management: Awareness of a large, active institutional investor holding a significant stake in the company.

Key Dates

Keywords

Taysha Gene Therapies, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common stock, institutional investor, gene therapy, SEC filing